• 四川大學(xué)華西醫(yī)院普外科、海扶治療中心(成都610041);

目的探討高強(qiáng)度聚焦超聲治療對肝癌細(xì)胞血道播散的影響。方法應(yīng)用NestedRTPCR技術(shù)檢測19例患者高強(qiáng)度聚焦超聲治療前、后外周血AFP mRNA的表達(dá),觀察其對肝癌細(xì)胞血道播散的影響。結(jié)果①高強(qiáng)度聚焦超聲治療前,19例肝癌患者外周血檢出AFP mRNA表達(dá)者11例(57.9%),良性疾病對照組均未檢出。治療前AFP mRNA表達(dá)陽性率與血清AFP水平、腫瘤直徑、門靜脈癌栓、遠(yuǎn)處轉(zhuǎn)移等臨床參數(shù)明顯相關(guān)(P<0.05)。②余8例治療前AFP mRNA表達(dá)陰性者,有2例于術(shù)后即刻轉(zhuǎn)為陽性,其中1例于72 h后又復(fù)轉(zhuǎn)為陰性; 19例患者于治療后1周時(shí)其AFP mRNA表達(dá)陽性率(31.6%)低于治療前,但差異無統(tǒng)計(jì)學(xué)意義(P gt;0.05)。③治療后1周時(shí),腫瘤直徑≤8 cm者AFP mRNA表達(dá)陽性率低于直徑 gt;8 cm者(P<0.05)。結(jié)論高強(qiáng)度聚焦超聲治療可能會降低肝癌的血道播散,特別是對于腫瘤直徑≤8 cm的肝癌患者,療效較好。

引用本文: 李富宇,劉紅,龍泉伊,蔣力生,許瑞華. 高強(qiáng)度聚焦超聲治療對肝癌患者外周血AFP mRNA的影響. 中國普外基礎(chǔ)與臨床雜志, 2004, 11(3): 247-249. doi: 復(fù)制

1. Farmer DG, Rosove MH, Shaked A, et al. Current treatment modalities for hepatocellular carcinoma [J]. Ann Surg, 1994; 219(3)∶ 236.
2. Yang R, Reilly CR, Rescorla FJ, et al. Highintensity focused ultrasound in the treatment of experimental liver cancer [J]. Arch Surg, 1991; 126(8)∶1002.
3. Oosterhof GO, Cornel EB, Smits GA, et al. Influence of highintensity focused ultrasound on the development of metastases [J]. Eur Urol, 1997; 32(1)∶91.
4. Komeda T, Fukuda Y, Sando T, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood [J]. Cancer, 1995; 75(9)∶2214.
5. Wang L, Tang ZY, Qin LX, et al. Highdose and longterm therapy with interferonalfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential [J]. Hepatology, 2000; 32(1)∶43.
6. Matsumura M, Niwa Y, Kato N, et al. Detection of alphafetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma [J]. Hepatology, 1994; 20(6)∶1418.
7. Prat F, Centarti M, Sibille A, et al. Extracorporeal highintensity focused ultrasound for VX2 liver tumors in the rabbit [J]. Hepatology, 1995; 21(3)∶832.
  1. 1. Farmer DG, Rosove MH, Shaked A, et al. Current treatment modalities for hepatocellular carcinoma [J]. Ann Surg, 1994; 219(3)∶ 236.
  2. 2. Yang R, Reilly CR, Rescorla FJ, et al. Highintensity focused ultrasound in the treatment of experimental liver cancer [J]. Arch Surg, 1991; 126(8)∶1002.
  3. 3. Oosterhof GO, Cornel EB, Smits GA, et al. Influence of highintensity focused ultrasound on the development of metastases [J]. Eur Urol, 1997; 32(1)∶91.
  4. 4. Komeda T, Fukuda Y, Sando T, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood [J]. Cancer, 1995; 75(9)∶2214.
  5. 5. Wang L, Tang ZY, Qin LX, et al. Highdose and longterm therapy with interferonalfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential [J]. Hepatology, 2000; 32(1)∶43.
  6. 6. Matsumura M, Niwa Y, Kato N, et al. Detection of alphafetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma [J]. Hepatology, 1994; 20(6)∶1418.
  7. 7. Prat F, Centarti M, Sibille A, et al. Extracorporeal highintensity focused ultrasound for VX2 liver tumors in the rabbit [J]. Hepatology, 1995; 21(3)∶832.